摘要
From Feb. 1989 to May 1996, 170 patients underwent valve replacement with bileaflet heart valve prosthesis. There were 13 early deaths (mortality of 7-65% ), and 6 late deaths. The Preoperative cardiac function (NYHA) was grade Ⅱ in 96 cases, Ⅳ in 35 cases and Ⅲ to Ⅳ in 77. 1%.Follow-up of the survivors from 3 to 87 (average 39) months showed that most of them could do light and moderate physical labor, and cardiac function was restored to grade Ⅰ～ Ⅱ in 96. 4%. Anti-coagulating bleeding is a common complicaion. However, severe embolism and valve dysfunction had not been found- The authors analysed the causes of death and follow-up data, then emphasized that it was necessary that valve replacement be performed as early as possible, and bileaflet heart valve substitute was the best choice. Furthermore, therapy of little dose anti-coagulating drug(warfarin 1.5～3- 0mg/d) is safe and dependable to most of the patients.
From Feb. 1989 to May 1996, 170 patients underwent valve replacement with bileaflet heart valve prosthesis. There were 13 early deaths (mortality of 7-65% ), and 6 late deaths. The Preoperative cardiac function (NYHA) was grade Ⅱ in 96 cases, Ⅳ in 35 cases and Ⅲ to Ⅳ in 77. 1%.Follow-up of the survivors from 3 to 87 (average 39) months showed that most of them could do light and moderate physical labor, and cardiac function was restored to grade Ⅰ～ Ⅱ in 96. 4%. Anti-coagulating bleeding is a common complicaion. However, severe embolism and valve dysfunction had not been found- The authors analysed the causes of death and follow-up data, then emphasized that it was necessary that valve replacement be performed as early as possible, and bileaflet heart valve substitute was the best choice. Furthermore, therapy of little dose anti-coagulating drug(warfarin 1.5～3- 0mg/d) is safe and dependable to most of the patients.
